Drug Trial Radar · NCT07787728
Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 14, 2025
Primary completion
Dec 16, 2025
Study completion Dec 16, 2025
Sponsor
- Lead sponsor
- Shanghai Minwei Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity characteristics of MWN109 injection in Chinese non-diabetic participants with overweight or obesity. A total of 40 participants were enrolled in the study. All participants were stratified and randomized by gender, and randomly assigned to 4 dose groups at a ratio of 1:1:1:1, with 10 participants in each group(8 participants received MWN109 injection, and 2 received placebo). Each treatment group will use a dose titration method to reach the target dose. The study includes a maximum screening period of up to 2 weeks, a 14-week treatment period and a 2-week follow-up period, totaling 18 weeks. The primary endpoint is the incidence of adverse events. The secondary endpoint is the pharmacokinetic characteristics.
Conditions
- Overweight , Obesity
Interventions
MWN109 1Drug
Administered SC, QW, 14 weeks
MWN109 2Drug
Administered SC, QW, 14 weeks
MWN109 3Drug
Administered SC, QW, 14 weeks
MWN109 4Drug
Administered SC, QW, 14 weeks
PlaceboDrug
Administered SC, QW, 14 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From Day 1 to Day 113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Yunnan University of Chinese Medicine (Yunnan Provincial Hospital of Traditional Chinese Medicine)
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.